.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
US Army
Dow
AstraZeneca
Cipla
Citi
US Department of Justice
QuintilesIMS
Fuji
Chubb

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202230

« Back to Dashboard

NDA 202230 describes LOSARTAN POTASSIUM, which is a drug marketed by Alembic Pharms Ltd, Apotex Corp, Aurobindo Pharma, Cadista Pharms, Hetero Labs Ltd V, Ipca Labs Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan, Prinston Inc, Sandoz, Teva, Torrent Pharms, Unichem Labs Ltd, Upsher-smith Labs, Viva Hlthcare, Vivimed Global, Watson Labs, West-ward Pharms Int, Zydus Pharms Usa Inc, Apotex, and Teva Pharms, and is included in thirty-six NDAs. It is available from sixty-six suppliers. Additional details are available on the LOSARTAN POTASSIUM profile page.

The generic ingredient in LOSARTAN POTASSIUM is hydrochlorothiazide; losartan potassium. There are thirty-one drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.

Summary for 202230

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202230

Suppliers and Packaging for NDA: 202230

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 202230 ANDA Macleods Pharmaceuticals Limited 33342-044 33342-044-10 90 TABLET, FILM COATED in 1 BOTTLE (33342-044-10)
LOSARTAN POTASSIUM losartan potassium TABLET;ORAL 202230 ANDA Macleods Pharmaceuticals Limited 33342-044 33342-044-07 30 TABLET, FILM COATED in 1 BOTTLE (33342-044-07)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:May 30, 2012TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:May 30, 2012TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength100MG
Approval Date:May 30, 2012TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Cipla
McKinsey
Deloitte
Cerilliant
Johnson and Johnson
Federal Trade Commission
Citi
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot